TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans

President Donald Trump has launched a new prescription drug pricing website, TrumpRx.gov, aiming to showcase his administration’s efforts to reduce drug costs in the United States. The website focuses heavily on negotiated discounts for popular GLP-1 weight-loss drugs, but experts say its overall impact for the broader population may be limited.

Unveiled during a White House event, TrumpRx.gov is presented as a central component of the administration’s drug pricing strategy. Trump has claimed the platform delivers immediate and significant savings to millions of Americans. However, as of its initial rollout, only five pharmaceutical companies have listed drugs on the site, despite earlier announcements that 16 major global drugmakers had agreed to “most-favored nation” pricing deals in exchange for tariff exemptions.

The website currently features discounts on fewer than 45 prescription drugs, with more than 30 coming from a single manufacturer, Pfizer. Many of the listed medications already have lower-cost generic alternatives, which limits the site’s value for consumers who are insured or already paying reduced prices through existing programs. According to health policy experts, most Americans may still save more by using their health insurance rather than relying on TrumpRx.gov, assuming their prescriptions are covered.

TrumpRx.gov does not sell drugs directly. Instead, it provides coupons or links to manufacturer-operated websites where patients can purchase medications at discounted rates. While advertised discounts range from 33% to more than 90% off list prices, the final out-of-pocket costs can remain high. For example, Pfizer’s arthritis drug Xeljanz is discounted by about one-third but still costs over $1,500 per month.

The most substantial savings appear in GLP-1 weight-loss drugs, with negotiated prices dropping from over $1,000 per month to as low as $149 to $350 for uninsured patients. Fertility drugs, such as Gonal-F from Merck KGaA’s EMD Serono unit, are also significantly discounted and may benefit patients whose treatments are typically not covered by insurance.

While TrumpRx.gov may help specific groups, analysts caution that the program’s narrow scope and limited drug selection reduce its overall effectiveness in lowering prescription drug costs nationwide.